• 1
    Compston, J.E. (2010) Management of glucocorticoid-induced osteoporosis. Nature Reviews in Rheumatology, 6, 8288.
  • 2
    Curtis, J.R., Westfall, A.O., Allison, J.J. et al. (2005) Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheumatism, 52, 24852494.
  • 3
    Feldstein, A.C., Elmer, P.J., Nichols, G.A. et al. (2005) Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporosis International, 16, 21682174.
  • 4
    van Staa, T.P., Leufkens, H.G. & Cooper, C. (2002) The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis International, 13, 777787.
  • 5
    Compston, J.E. (2007) Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Current Rheumatology Reports, 9, 7884.
  • 6
    Kanis, J.A., Johansson, H., Oden, A. et al. (2004) A meta-analysis of prior corticosteroid use and fracture risk. Journal of Bone and Mineral Research, 19, 893899.
  • 7
    Luengo, M., Picado, C., Del Rio, L. et al. (1990) Treatment of steroid-induced osteopenia with calcitonin in corticosteroid dependent asthma. A one-year follow-up study. American Reviews of Respiratory Disease, 142, 104107.
  • 8
    van Staa, T.P., Leufkens, H.G., Abenhaim, L. et al. (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford), 39, 13831389.
  • 9
    Ip, M., Lam, K., Yam, L. et al. (1994) Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest, 105, 17221727.
  • 10
    Toogood, J.H., Baskerville, J.C., Markov, A.E. et al. (1995) Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. Journal of Allergy and Clinical Immunology, 96, 157166.
  • 11
    Wong, C.A., Walsh, L.J., Smith, C.J. et al. (2000) Inhaled corticosteroid use and bone mineral density in patients with asthma. Lancet, 355, 13991403.
  • 12
    van Staa, T.P., Leufkens, H.G. & Cooper, C. (2001) Use of inhaled corticosteroids and risk of fractures. Journal of Bone and Mineral Research, 16, 581588.
  • 13
    van Staa, T.P., Laan, R.F., Barton, I.P. et al. (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis & Rheumatism, 48, 32243229.
  • 14
    Kanis, J.A. (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359, 19291936.
  • 15
    University of Sheffield. FRAX®—WHO Fracture Risk Assessment Tool [online]. Available from:
  • 16
    Grossman, J.M., Gordon, R., Ranganath, V.K. et al. (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Research, 62, 15151526 Available from:
  • 17
    Guidelines working Group for the Bone and Tooth Society, National Osteoporosis Society and Royal College of Physicians. 2002 Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Royal College of Physicians, London.
  • 18
    Homik, J., Cranney, A., Shea, B. et al. (1999) Bisphosphonates for steroid induced osteoporosis. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD001347.doi:10.1002/14651858. CD001347.
  • 19
    Adachi, J.D., Bensen, W.G., Brown, J. et al. (1997) Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. New England Journal of Medicine, 337, 382387.
  • 20
    Saag, K.G., Emkey, R., Schnitzer, T.J. et al. (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. New England Journal of Medicine, 339, 292299.
  • 21
    Adachi, J.D., Saag, K.G., Delmas, P.D. et al. (2001) Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis & Rheumatism, 44, 202211.
  • 22
    Stoch, S.A., Saag, K.G., Greenwald, M. et al. (2009) Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial. Journal of Rheumatology, 36, 17051714.
  • 23
    Cohen, S., Levy, R.M., Keller, M. et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a 12 month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis & Rheumatism, 42, 23092318.
  • 24
    Reid, D.M., Hughes, R.A., Laan, R.F. et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. Journal of Bone and Mineral Research, 15, 10061013.
  • 25
    Wallach, S., Cohen, S., Reid, D.M. et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcified Tissue International, 67, 277285.
  • 26
    Reid, D.M., Adami, S., Devogelaer, J.P. et al. (2001) Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcified Tissue International, 69, 242247.
  • 27
    Reid, D.M., Devogelaer, J.P., Saag, K. et al. (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet, 373, 12531263.
  • 28
    Abrahamsen, B. (2010) Adverse effects of bisphosphonates. Calcified Tissue International, 86, 421435.
  • 29
    Saag, K.G., Shane, E., Boonen, S. et al. (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. New England Journal of Medicine, 357, 20282039.
  • 30
    Saag, K.G., Zanchetta, J.R., Devogelaer, J.P. et al. (2009) Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism, 60, 33463355.